Primecap Management Co. CA Invests $7.14 Million in IQVIA Holdings Inc. $IQV

Primecap Management Co. CA bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 36,962 shares of the medical research company’s stock, valued at approximately $7,142,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Korea Investment CORP bought a new position in IQVIA in the second quarter worth about $13,918,000. BlackRock Inc. acquired a new position in IQVIA during the 2nd quarter valued at about $2,811,292,000. Concurrent Investment Advisors LLC grew its position in IQVIA by 36.0% in the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock worth $2,693,000 after purchasing an additional 3,161 shares during the last quarter. Deutsche Bank AG acquired a new stake in shares of IQVIA in the second quarter valued at approximately $143,074,000. Finally, Focus Partners Advisor Solutions LLC acquired a new stake in shares of IQVIA in the second quarter valued at approximately $976,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. Royal Bank Of Canada boosted their price objective on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Mizuho increased their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. HSBC reissued a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Finally, William Blair raised shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Transactions at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 12,913 shares of company stock worth $3,098,793. Corporate insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

IQV opened at $261.57 on Thursday. The company has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $262.51. The business has a 50 day moving average price of $218.41 and a two-hundred day moving average price of $188.59.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same period last year, the firm earned $2.81 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.